title: Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene.
abstract: OBJECTIVE
  To study a new method for treating squamous cell carcinoma of the head and neck using a survivin antisense gene.
  
  
  METHODS
  An adenoviral vector encoding surviving antisense was used for in vitro and in vivo experiments. KB cells were treated with pAd.CMV[cytomegalovirus]-antisurvivin. Western blot analysis, in vitro cytotoxic assay, and in vivo experiment were performed.
  
  
  METHODS
  In vitro and in vivo study of head and neck cancer cell line KB.
  
  
  METHODS
  Male, 5-week-old BALB/c nude mice.
  
  
  METHODS
  Expression of survivin was assessed using Western blot analysis. The effect of antisurvivin to KB cells was measured by cytotoxic assay (in vitro) and tumor volume (in vivo).
  
  
  RESULTS
  In the in vitro experiments, transduction of the survivin antisense gene caused a nearly 12-fold increase in the sensitivity of KB cells to cisplatin, as reflected by the 50% inhibitory concentration. In in vivo experiments in nude mice, tumor growth was more inhibited by the combination of cisplatin and survivin antisense gene transduction compared with either alone.
  
  
  CONCLUSIONS
  These findings suggest that survivin targeting with adenoviral antisense vectors might be used for selective therapy of squamous cell carcinomas of the head and neck.
authors.affiliation: Department of Otorhinolaryngology, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan. Kojimah@jikei.ac.jp
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kojima
authors.forename: Minoru
authors.initials: M
authors.lastname: Iida
authors.forename: Yuichirou
authors.initials: Y
authors.lastname: Yaguchi
authors.forename: Rie
authors.initials: R
authors.lastname: Suzuki
authors.forename: Norihiko
authors.initials: N
authors.lastname: Hayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Moriyama
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Manome
mesh_terms: D000256:Adenoviridae; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology*; D015853:Cysteine Proteinase Inhibitors / Q000235:genetics / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000235:genetics / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology*; D000077022:Survivin; D014162:Transfection
chemical_list: C107489:BIRC5 protein, human; D015853:Cysteine Proteinase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D000077022:Survivin; D002945:Cisplatin